News | August 18, 2023
Honeywell, Recipharm to speed development of inhalers
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Integration of modern and traditional medicine to facilitate the illness to wellness journey
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Subscribe To Our Newsletter & Stay Updated
